One of the largest and the most sustainability challenge for all pharmaceutical companies that they are facing great changes to the industry (new products and services), With a shift in market needs towards medicines that are targeted to specific diseases and a payer community that is looking for lower cost and improved outcomes is creating strategic issues over where future investments should be made, While difficult ethical considerations persist for companies weighing the options, the less immediately profitable choices are quickly becoming as much strategic as ethical.
Cambridge Consulting can help in addressing your problem whether it is a pharmaceutical, biotech, natural health, personal care products, or medical devices you recognize, and we make the most of the opportunities that arise as the industry develops and dig to address the complexity of that market. We continuously strive to keep abreast of industry trends, drivers and issues through sharing global knowledge and industry insights. Then we will help provide the sort of skills that manufacturers of pharmaceutical products require to make sure that their products are of higher caliber.
India is one of the fastest-growing pharmaceutical markets in the world, and its market size has nearly doubled since 2005. The Indian pharmaceutical market is expected to reach US$ 20 billion by 2015, growing at a compound annual growth rate (CAGR) of 11.7 % during 2005–2015 and establish its presence among the world’s leading 10 markets. India is also the third-largest market in the world in terms of volume and fourteenth in terms of value.
India accounts for 8 % of global pharmaceutical production. Indian firms produce about 60,000 generic brands across 60 therapeutic categories. In addition, Indian firms manufacture approximately 500 different active pharmaceutical ingredients (APIs). Manufacturing costs in India are approximately 35 to 40 % of those in the US due to low installation and manufacturing costs.
Moreover, India is expected to be among the world’s top five innovative hubs with contributions of around 50 % to drugs discovered worldwide. India is a fast-growing custom manufacturing outsourcing (CMO) and custom research outsourcing (CRO) destination with a growth rate for CMO thrice the global market rate.
Exports of pharmaceutical products have more than doubled over three years to around US$ 5.2 billion in 2009–2010. In 2009, India had more than120 US FDA-approved plants in addition to 84 UK MHRA-approved plants. The GoI has also introduced zero duty for technology upgrades in the pharmaceutical sector through the Export Promotion Capital Goods Scheme (EPCG) scheme.
Biotechnology has generated a wide range of products, benefiting a number of economic sectors, including but not limited to, food generation, medical products, cleaning products and waste treatment.
Cambridge Consulting is able to assist firms in the biotechnology sector, by recognizing new technologies, organizations and other advances in the biotechnology sector. Cambridge Consulting is able to develop an expansion strategy for the sector, along with helping clients in managing partnerships, joint ventures, acquisitions and licensing strategies. Cambridge Consulting can also assist in forming laboratories and other essential facilities.
Medical Products and Diagnostics
The provision of medical supplies, products and diagnostic instruments is an essential component of any nation’s sustainability. These range from simple pharmaceutical products to essential medical tools.
Cambridge Consulting analyzes the management of medical care firms and facilities, performing diagnostics of their operating procedures, after which it generates new operating structures for firms in the sector, at competitive prices. Cambridge Consulting will also perform corporate design optimization, thus leading to the creation of a supply chain appropriate to the scale of the company’s operations.
Many pharmaceutical facilities also have animal health applications (for example, farm animal health). Cambridge Consulting assists clients in exploring markets for animal health products and services.
Cambridge Consulting is also capable of creating portfolio strategies, along with solid research and development programs, as well as search for new drugs and animal care methods, in order to meet the demand for animal care.
Medicine Patient Information Leaflets
Any information regarding pharmaceutical products, wherever it may be found (whether on the product itself, on a leaflet, website or other source), must conform to international standards. It must pass ‘user-friendly’ tests in order to show that the average consumer can understand the information therein.
Cambridge Consulting is able to write and test information documents (whether leaflets or other formats) for pharmaceutical products. This is to guarantee that the pharmaceutical product will be utilized in a safe manner, for its proper purpose, and that consumers understand both the intended effects and side effects of any pharmaceutical product.
People and Change Management
Obtaining the maximum possible output from a firm’s employees is one of the paths to maintaining a firm’s competitive advantage. While effective strategies, organizational structures and the proper usage of technology are all essential, they are not enough to maintain productivity and growth. It is the employees and management of the firm that have to research, experiment and implement the methods for positive change.
Cambridge Consulting is able to assist in the restructuring of a firm, so that the capabilities of the staff and leadership are properly harnessed, in line with the firm’s strategic objectives. Cambridge Consulting will assist clients in matching the correct individuals (based on skill levels) to the right position in the company.
An effective R&D strategy
Research and Development (the generation of new products and services) is more essential today than ever before, due to increasing consumer demand, varieties of taste, and competition. Consistent R&D is vital, in order to keep a pulse on consumers, thus providing the accurate data needed to modify firm products, services or policies. The most significant R&D focuses on long-term issues, and is designed with specific aims in mind.
Cambridge Consulting is capable of providing the pharmaceutical sector with the R&D it needs to expand and thrive. Cambridge Consulting is also capable of assisting firms in the improvement of their R&D capabilities, as well as assist in human resource management (within the R&D Department), capable of boosting the effectiveness of this department significantly
Risk management strategy
Risk management is a strategic safety program designed to decrease product risk by using one or more interventions or tools. It provides methods to identify risks that could affect the safety, quality, reliability, or durability of a product, process or program and organizes the risks in order to evaluate them and plan appropriate responses. Sometimes this is referred to as a “Hazards Analysis” which is often used in conjunction with a “Failure Modes and Effects Analysis.
Here at Cambridge Consulting we submit for every product an approval to consider how to minimize risks from the product’s use. We may include product labeling, risk assessment, pharmacovigilance, and special studies or interventions. In addition, we evaluate the priority and severity of an identified risk that threatens the safety, quality, reliability, or durability of a product, process, or program. By which these Evaluation Techniques allow the project team to assess the risk relatively quickly and to organize the team for subsequent action.